Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Double-blind,Placebo-controlled Study for Evaluation of Efficiency, Safety,Tolerance and Pharmacokinetics of Different Doses of Remegal in Additional Therapy for Patients With Refractory Partial Seizures

NCT01179854 is registered in ClinicalTrials.gov with Valexfarm as lead sponsor.

NCT NCT01179854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01179854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Double-blind,Placebo-controlled Study for Evaluation of Efficiency, Safety,Tolerance and Pharmacokinetics of Different Doses of Remegal in Additional Therapy for Patients With Refractory Partial Seizures
Lead sponsor
Valexfarm
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2009
Completion date
September 30, 2011
Enrollment
60 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

drug safety, normal drug tolerance, self efficacy